# A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

> **NCT04707313** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 628 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Placebo (Cohorts 1 and 2)
- **DRUG:** PF-06882961 (Cohorts 1 and 2)
- **DRUG:** Placebo (Cohort 3)
- **DRUG:** PF-06882961 (Cohort 3)

## Key facts

- **NCT ID:** NCT04707313
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-29
- **Primary completion:** 2023-09-13
- **Final completion:** 2023-10-11
- **Target enrollment:** 628 (ACTUAL)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04707313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04707313, "A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04707313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*